AR053272A1 - Determinacion de responsivos a la quimioterapia - Google Patents
Determinacion de responsivos a la quimioterapiaInfo
- Publication number
- AR053272A1 AR053272A1 ARP060101849A ARP060101849A AR053272A1 AR 053272 A1 AR053272 A1 AR 053272A1 AR P060101849 A ARP060101849 A AR P060101849A AR P060101849 A ARP060101849 A AR P060101849A AR 053272 A1 AR053272 A1 AR 053272A1
- Authority
- AR
- Argentina
- Prior art keywords
- phosphorylated
- protein
- refers
- biological sample
- cancer cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente se refiere a un método para determinar si una muestra biologica que contiene células cancerígenas de pulmon humanas es sensible a una combinacion de un inhibidor del receptor del factor de crecimiento epidérmico y un agente quimioterapéutico mediante a determinacion de la sobreexpresion de una proteína AKT fosforilada una proteína MAPK fosforilada en la muestra biologica. La presente también se refiere a métodos para obtener un agente candidato o seleccionar una composicion para inhibir la progresion de las células cancerígenas de pulmon en un paciente en el que se utiliza una proteína AKT fosforilada o una proteína MAPK fosforilada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05010244 | 2005-05-11 | ||
EP05011070 | 2005-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053272A1 true AR053272A1 (es) | 2007-04-25 |
Family
ID=36733489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101849A AR053272A1 (es) | 2005-05-11 | 2006-05-09 | Determinacion de responsivos a la quimioterapia |
Country Status (14)
Country | Link |
---|---|
US (2) | US7655414B2 (es) |
EP (1) | EP1889066A1 (es) |
JP (2) | JP4847518B2 (es) |
KR (1) | KR100962162B1 (es) |
CN (1) | CN102854315A (es) |
AR (1) | AR053272A1 (es) |
AU (1) | AU2006245962B8 (es) |
BR (1) | BRPI0609096A2 (es) |
CA (1) | CA2605151A1 (es) |
IL (1) | IL185631A (es) |
MX (1) | MX2007013973A (es) |
NO (1) | NO20074389L (es) |
RU (1) | RU2416096C2 (es) |
WO (1) | WO2006119980A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
US20080108091A1 (en) * | 2006-08-07 | 2008-05-08 | Hennessy Bryan T | Proteomic Patterns of Cancer Prognostic and Predictive Signatures |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
JP4795203B2 (ja) * | 2006-11-13 | 2011-10-19 | シスメックス株式会社 | アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム |
AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
EP2179291B1 (en) | 2007-07-13 | 2014-10-22 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
CA2694587A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
CA2695064A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive markers for egfr inhibitors treatment |
MX2010001571A (es) * | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
CA2700238A1 (en) | 2007-10-15 | 2009-04-23 | Precision Therapeutics, Inc. | Methods for selecting active agents for cancer treatment |
WO2009089521A2 (en) * | 2008-01-10 | 2009-07-16 | Nuvera Biosciences, Inc. | Predictors for evaluating response to cancer therapy |
ES2398618T3 (es) | 2008-02-25 | 2013-03-20 | Nestec S.A. | Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos |
WO2009126543A1 (en) * | 2008-04-08 | 2009-10-15 | Nuclea Biomarkers, Llc | Biomarker panel for prediction of recurrent colorectal cancer |
CA2721687A1 (en) * | 2008-05-14 | 2009-11-19 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
US20100311084A1 (en) * | 2008-05-14 | 2010-12-09 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
WO2009148896A2 (en) | 2008-05-29 | 2009-12-10 | Nuclea Biotechnologies, LLC | Anti-phospho-akt antibodies |
NZ606687A (en) * | 2009-01-14 | 2014-08-29 | Us Health | Ratio based biomarkers and methods of use thereof |
AU2010249401B2 (en) * | 2009-05-22 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Akt phosphorylation at Ser473 as an indicator for taxane-based chemotherapy |
JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
EP2751562B1 (en) | 2011-09-02 | 2015-09-16 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
EP2810066B1 (en) * | 2012-01-24 | 2019-07-31 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
JP6215234B2 (ja) * | 2012-01-24 | 2017-10-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 鼻咽頭癌の治療方法 |
JP5383836B2 (ja) | 2012-02-03 | 2014-01-08 | ファナック株式会社 | 検索ウィンドウを自動的に調整する機能を備えた画像処理装置 |
SI2914296T2 (sl) * | 2012-11-01 | 2022-01-31 | Infinity Pharmaceuticals, Inc. | Zdravljenje raznih vrst raka z uporabo modulatorjev izooblik PI3-kinaze |
RU2557976C2 (ru) * | 2013-05-07 | 2015-07-27 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ определения чувствительности клеток рака легкого к цисплатину на основании уровней экспрессии маркерных генов и набор для его осуществления |
EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
US11371099B2 (en) | 2015-11-30 | 2022-06-28 | Mayo Foundation For Medical Education And Research | HEATR1 as a marker for chemoresistance |
SG11201809317VA (en) * | 2016-05-09 | 2018-11-29 | Inst Nat Sante Rech Med | Methods for classifying patients with a solid cancer |
RU2738167C1 (ru) * | 2020-06-08 | 2020-12-09 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5562925A (en) | 1970-04-20 | 1996-10-08 | Research Corporation Tech. Inc. | Anti-tumor method |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
CN100340575C (zh) * | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
MXPA03004029A (es) * | 2000-11-09 | 2004-02-12 | Oncolytics Biotech Inc | Metodos para tratamiento de trastornos proliferativos celulares. |
DE08002964T1 (de) * | 2001-02-27 | 2009-09-03 | Blanchette Rockefeller Neurosciences Institute | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
CA2439404A1 (en) * | 2001-03-07 | 2002-09-12 | Bio-Rad Laboratories Inc. | Assay system for simultaneous detection and measurement of multiple modified cellular proteins |
JP2003189866A (ja) * | 2001-12-26 | 2003-07-08 | Sankyo Co Ltd | 骨吸収抑制剤探索法 |
US8008003B2 (en) * | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
EP1597558A2 (en) | 2003-01-08 | 2005-11-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
JP2004229547A (ja) * | 2003-01-29 | 2004-08-19 | Nobuhiko Nomura | アシル化ホモセリンラクトン阻害物質をスクリーニングする方法 |
US7537906B2 (en) * | 2003-01-29 | 2009-05-26 | Nobuhiko Nomura | Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone |
JP2006521793A (ja) * | 2003-02-06 | 2006-09-28 | ゲノミック ヘルス, インコーポレイテッド | Egfrインヒビター薬物に応答性の遺伝子発現マーカー |
JP2004257783A (ja) * | 2003-02-25 | 2004-09-16 | Jgs:Kk | 金属錯化合物抗癌剤に対する癌細胞の耐性の検査方法及び該耐性を低減させるための薬剤 |
AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
-
2006
- 2006-05-09 AR ARP060101849A patent/AR053272A1/es not_active Application Discontinuation
- 2006-05-10 JP JP2008508171A patent/JP4847518B2/ja not_active Expired - Fee Related
- 2006-05-10 WO PCT/EP2006/004370 patent/WO2006119980A1/en active Application Filing
- 2006-05-10 RU RU2007145514/15A patent/RU2416096C2/ru not_active IP Right Cessation
- 2006-05-10 MX MX2007013973A patent/MX2007013973A/es active IP Right Grant
- 2006-05-10 CA CA002605151A patent/CA2605151A1/en not_active Abandoned
- 2006-05-10 BR BRPI0609096-6A patent/BRPI0609096A2/pt not_active IP Right Cessation
- 2006-05-10 KR KR1020077024114A patent/KR100962162B1/ko not_active IP Right Cessation
- 2006-05-10 US US11/431,241 patent/US7655414B2/en not_active Expired - Fee Related
- 2006-05-10 CN CN2012103217904A patent/CN102854315A/zh active Pending
- 2006-05-10 AU AU2006245962A patent/AU2006245962B8/en not_active Ceased
- 2006-05-10 EP EP06742856A patent/EP1889066A1/en not_active Withdrawn
-
2007
- 2007-08-29 NO NO20074389A patent/NO20074389L/no not_active Application Discontinuation
- 2007-08-30 IL IL185631A patent/IL185631A/en not_active IP Right Cessation
-
2009
- 2009-11-19 US US12/621,796 patent/US20100196931A1/en not_active Abandoned
-
2011
- 2011-08-16 JP JP2011178014A patent/JP2012021997A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2006245962B8 (en) | 2011-12-08 |
US20070054330A1 (en) | 2007-03-08 |
CA2605151A1 (en) | 2006-11-16 |
US20100196931A1 (en) | 2010-08-05 |
US7655414B2 (en) | 2010-02-02 |
BRPI0609096A2 (pt) | 2010-02-17 |
AU2006245962B2 (en) | 2011-11-03 |
MX2007013973A (es) | 2008-01-11 |
RU2416096C2 (ru) | 2011-04-10 |
IL185631A (en) | 2011-12-29 |
RU2007145514A (ru) | 2009-06-20 |
AU2006245962A1 (en) | 2006-11-16 |
WO2006119980A1 (en) | 2006-11-16 |
EP1889066A1 (en) | 2008-02-20 |
KR20070116641A (ko) | 2007-12-10 |
IL185631A0 (en) | 2008-01-06 |
KR100962162B1 (ko) | 2010-06-10 |
JP2008538817A (ja) | 2008-11-06 |
CN102854315A (zh) | 2013-01-02 |
JP4847518B2 (ja) | 2011-12-28 |
NO20074389L (no) | 2007-12-06 |
JP2012021997A (ja) | 2012-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053272A1 (es) | Determinacion de responsivos a la quimioterapia | |
UA116618C2 (uk) | СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b | |
RS51859B (en) | METHOD FOR ANTICIPATING THE RESPONSE TO TREATMENT OF HER DIMENSION INHIBITORS | |
AR051524A1 (es) | Seleccion de pacientes para una terapia con un inhibidor de her | |
NZ593229A (en) | Gene expression markers (gadd45b) for colorectal cancer prognosis | |
AR051523A1 (es) | Metodo para medir la resistencia o sensibilidad a docetaxel | |
MX2010005081A (es) | Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco. | |
HK1114883A1 (en) | Skin aging marker and technique for use thereof | |
Miyamoto et al. | Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity | |
ATE489622T1 (de) | Verfahren zur beurteilung der malignität einer säuger-krebszelle | |
CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
DK1761651T3 (da) | MNRA-forhold i urinsedimenter og/eller urin som en prognostisk og/eller teranostisk markør for prostatakræft | |
ES2527776T3 (es) | Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin | |
WO2014170497A3 (en) | Method for identifying the quantitative cellular composition in a biological sample | |
WO2008021290A8 (en) | Organ-specific proteins and methods of their use | |
TW200716982A (en) | Measuring thrombin activity in whole blood | |
BR112012014925A2 (pt) | compostos promotores de replicação de células beta e métodos de uso dos mesmos | |
MX2010008496A (es) | Metodo para la determinacion de sensibilidad a agente anticancerigeno. | |
ES2570631T3 (es) | Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal | |
WO2008037700A3 (en) | Methods for breast cancer prognosis | |
Choi et al. | Lyso-globotriaosylceramide downregulates KCa3. 1 channel expression to inhibit collagen synthesis in fibroblasts | |
ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
ATE505539T1 (de) | Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren | |
MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
WO2009093856A3 (ko) | 생물학적 의약품으로부터 마이코플라즈마를 검출하기 위한 pcr 프라이머 세트 및 이를 포함하는 마이코플라즈마 검출용 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |